These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 32229581)
21. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. Cankurtaran ES; Ozalp E; Soygur H; Cakir A J Natl Med Assoc; 2006 Aug; 98(8):1353-5. PubMed ID: 16916137 [TBL] [Abstract][Full Text] [Related]
23. Metformin intake associates with better cognitive function in patients with Huntington's disease. Hervás D; Fornés-Ferrer V; Gómez-Escribano AP; Sequedo MD; Peiró C; Millán JM; Vázquez-Manrique RP PLoS One; 2017; 12(6):e0179283. PubMed ID: 28632780 [TBL] [Abstract][Full Text] [Related]
24. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108 [TBL] [Abstract][Full Text] [Related]
25. Comparing Risperidone and Olanzapine to Tetrabenazine for the Management of Chorea in Huntington Disease: An Analysis from the Enroll-HD Database. Schultz JL; Kamholz JA; Nopoulos PC; Killoran A Mov Disord Clin Pract; 2019 Feb; 6(2):132-138. PubMed ID: 30838312 [TBL] [Abstract][Full Text] [Related]
26. Is deep brain stimulation effective in Huntington's Disease? - a systematic literature review. Kaczyńska J; Sitek EJ; Witkowski G; Rudzińska-Bar M; Janik P; Sławek J; Edwin EMG; Zielonka D Neurol Neurochir Pol; 2022; 56(4):299-307. PubMed ID: 35792559 [TBL] [Abstract][Full Text] [Related]
34. Globus pallidus degeneration and clinicopathological features of Huntington disease. Singh-Bains MK; Tippett LJ; Hogg VM; Synek BJ; Roxburgh RH; Waldvogel HJ; Faull RL Ann Neurol; 2016 Aug; 80(2):185-201. PubMed ID: 27255697 [TBL] [Abstract][Full Text] [Related]
35. Is non-recognition of choreic movements in Huntington disease always pathological? Justo D; Charles P; Daunizeau J; Delmaire C; Gargiulo M; Hahn-Barma V; Naccache L; Durr A Neuropsychologia; 2013 Mar; 51(4):748-59. PubMed ID: 23262076 [TBL] [Abstract][Full Text] [Related]
36. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study. Jacobs M; Hart EP; van Zwet EW; Bentivoglio AR; Burgunder JM; Craufurd D; Reilmann R; Saft C; Roos RA; J Neurol; 2016 Oct; 263(10):2080-5. PubMed ID: 27435968 [TBL] [Abstract][Full Text] [Related]
37. Huntington's disease: present treatments and future therapeutic modalities. Bonelli RM; Wenning GK; Kapfhammer HP Int Clin Psychopharmacol; 2004 Mar; 19(2):51-62. PubMed ID: 15076012 [TBL] [Abstract][Full Text] [Related]
38. Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Fenney A; Jog MS; Duval C Brain Res; 2008 Feb; 1193():67-75. PubMed ID: 18177845 [TBL] [Abstract][Full Text] [Related]
39. Ziprasidone in Huntington's disease: the first case reports. Bonelli RM; Mayr BM; Niederwieser G; Reisecker F; Kapfhammer HP J Psychopharmacol; 2003 Dec; 17(4):459-60. PubMed ID: 14870962 [TBL] [Abstract][Full Text] [Related]
40. Emerging drug therapies in Huntington's disease. Mason SL; Barker RA Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]